Account
Publications
25.10.2023
ISPOR Europe 2023: How Aware Are Biotech and Pharm...

Our research aims to gauge awareness of the new EU HTA process within the pharmaceutical industry in...

Read more
Articles
08.08.2023
How to get payer scientific advice between now and...

Our market access experts provide an overview of how to get payer scientific advice between Septembe...

Read more
Articles
02.05.2023
Unveiling the Progress of a Coordinated HTA Networ...

We explore the coordinated HTA networks involved in EUnetHTA, define the HTACG and the deliverables ...

Read more
Webinar
27.04.2023
Implications of the EU HTA Process for Manufacture...

Our experts discuss the latest news and updates on the EU HTA process, including implications for ma...

Read more
Case Studies
26.04.2023
Optimising trial design through the EUnetHTA

Our clients have been developing new drugs for crowded, rapidly evolving therapy areas, with uncerta...

Read more
Articles
20.04.2023
EU HTA and what it means for manufacturers

Oncology products, advanced therapy medicinal products (ATMPs) and medical devices are entering the ...

Read more
Articles
03.04.2023
What is the joint clinical assessment and what doe...

We explore what the joint clinical assessment (JCA) is, its process and what future developments may...

Read more
News
30.03.2023
PMA Insights: Week 13 SPECIAL EDITION – Worl...

We summarise the World EPA Congress 2023 including plenary sessions on EU HTA, market archetypes, he...

Read more
News
04.01.2023
PMA Insights: Week 1

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Articles
08.12.2022
EU HTA – looking back on 2022

Our market access experts cover the changes to the joint EU HTA process that occurred in 2022 and wh...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.